BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Morphotek Announces Initiation of Phase I Study of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 in Solid Tumors With Folate Receptor Alpha Expression

  The Phase I trial, which is being conducted in Japan and referred to as MORAb-202-J081-101, is a first-in-human, dose-escalation study evaluating the safety and preliminary efficacy of MORAb-202 in patients with solid tumors that express FRA.

  December 4, 2017

   · 

  8 min read
• Drug Development

  Foresee Pharma Announces Results From Phase I Clinical Studies

  The objectives of these studies were to evaluate the safety, tolerability, and pharmacokinetics of oral ascending doses of FP-025 in healthy subjects.

  December 4, 2017

   · 

  3 min read
• Policy

  Breckenridge Pharmaceutical Announces Final Approval of its ANDA Megestrol Acetate Oral Suspension (Megace ES)

  The company will launch immediately.

  December 4, 2017

   · 

  1 min read
• AC Immune Shares Insights From Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer’s and Other Neurodegenerative Diseases

  The meeting featured presentations by KOLs Khalid Iqbal, PhD (New York State Institute for Basic Research in Developmental Disabilities) and Michael Rafii, MD, PhD (UC San Diego and USC).

  December 4, 2017

   · 

  5 min read
• Cobra Biologics Wins ‘Company of the Year’ and ‘Technical Services’ Awards in Double Success at 2017 Bionow Awards

  Cobra Biologics is very proud to have been named as Company of the Year as well as being presented with the Technical Service Award in this year’s Bionow Awards.

  December 4, 2017

   · 

  1 min read
• Almac Discovery Publishes USP7 Inhibitors From UbiPlex Platform

  Almac Discovery has today published its findings on the discovery and characterisation of highly potent, selective and reversible inhibitors of USP7 in the journal Nature Chemical Biology.

  December 4, 2017

   · 

  1 min read
• Business

  curasan Signs New Cooperation With Implantcast for the DACH-Region

  curasan AG has signed an exclusive distribution agreement with Implantcast GmbH, Buxtehude, Germany.

  December 4, 2017

   · 

  4 min read
• Business

  Export Sales of Curasan Continue to Rise

  curasan AG has further consolidated its export business in the third quarter.

  December 4, 2017

   · 

  4 min read
• New Analysis Shows High Rates of Skin Clearance as Measured by Absolute PASI in Patients With Moderate to Severe Plaque Psoriasis Treated With Janssen’s Tremfya (Guselkumab)

  Janssen presented a new analysis from VOYAGE 1 assessing efficacy responses based on absolute PASI, as reported through two years of TREMFYA treatment in adult patients with moderate to severe psoriasis.

  December 4, 2017

   · 

  3 min read
• AgriLabs Develops Master Seeds for Adenovirus Vectored Foot-and-Mouth Disease Vaccines

  This new technology allows FMD vaccines to be made without the biosecurity hazard of having actual FMD virus in a U.S. manufacturing facility.

  December 4, 2017

   · 

  2 min read